Cemiplimab significantly improved overall survival and progression-free survival compared to chemotherapy in advanced NSCLC with high PD-L1 expression. The EMPOWER-Lung 1 trial showed a median OS of ...
Google Cloud is moving forward with plans to launch its own layer-1 (L1) blockchain, positioning the network as neutral infrastructure for global finance at a time when fintech competitors are ...
Burmese pythons, native to South Asia, are an invasive species in Florida, posing a threat to the ecosystem. The Florida Python Challenge, a 10-day competition, encourages hunters to remove Burmese ...
NEW ORLEANS—A first-in-class peptide-based PET tracer, 18 F-AlF-NOTA-PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer 18 ...
Introduction: Epidermal growth factor receptor 2 (HER2) and programmed cell death ligand 1 (PD-L1) are pivotal therapeutic targets for advanced gastric cancer (GC). Nevertheless, the correlation ...
Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...
Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer. In a study, ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by ...
An expert discusses how enthusiasm for adjuvant anti–PD-1 therapy varies based on key factors. Receipt of neoadjuvant chemotherapy (NAC), nodal involvement, positive margins, variant histology, and PD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback